Literature DB >> 19513719

Small hypervascular hepatocellular carcinomas: value of "washout" on gadolinium-enhanced dynamic MR imaging compared to superparamagnetic iron oxide-enhanced imaging.

Jeong-Sik Yu1, Jae-Joon Chung, Joo Hee Kim, Ki Whang Kim.   

Abstract

The aim of this study was to retrospectively compare the value of "washout" on dynamic MR imaging with superparamagnetic iron oxide (SPIO)-enhanced imaging features of small hepatocellular carcinoma (HCC). A total of 74 small (5-30 mm) hypervascular HCCs in 42 cirrhotic patients who underwent double contrast material-enhanced MR imaging were evaluated to determine the presence of washout in the portal or equilibrium phase of gadolinium-enhanced dynamic imaging and decreased uptake of SPIO on T2*-weighted imaging. HCCs were verified histologically (n = 13) or by serial follow-up imaging studies (n = 61). According to the size of the lesions, 27 vs. 73% (<10 mm, n = 15; P = 0.016 on McNemar test), 39 vs. 79% (10-14 mm, n = 28; P = 0.002), 50 vs. 93% (15-20 mm, n = 14; P = 0.031), and 82 vs. 100% (>20 mm, n = 17; P = 0.250) of the lesions showed washout vs. decreased SPIO accumulation respectively. The larger the lesion, the higher the prevalence of washout or decreased SPIO uptake (P = 0.004 or P = 0.036, respectively, on Mantel-Haenszel test). In many small hypervascular HCCs up to 2 cm, SPIO-enhanced MR imaging offers essential information for early diagnosis in the absence of washout on dynamic imaging.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19513719     DOI: 10.1007/s00330-009-1465-8

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  33 in total

1.  Arterioportal shunts in cirrhotic patients: evaluation of the difference between tumorous and nontumorous arterioportal shunts on MR imaging with superparamagnetic iron oxide.

Authors:  K Mori; H Yoshioka; Y Itai; Y Okamoto; H Mori; N Takahashi; Y Saida
Journal:  AJR Am J Roentgenol       Date:  2000-12       Impact factor: 3.959

2.  Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver.

Authors:  J Bruix; M Sherman; J M Llovet; M Beaugrand; R Lencioni; A K Burroughs; E Christensen; L Pagliaro; M Colombo; J Rodés
Journal:  J Hepatol       Date:  2001-09       Impact factor: 25.083

3.  Improving the prediction of hepatocellular carcinoma in cirrhotic patients with an arterially-enhancing liver mass.

Authors:  Jorge A Marrero; Hero K Hussain; Hahn V Nghiem; Ramsey Umar; Robert J Fontana; Anna S Lok
Journal:  Liver Transpl       Date:  2005-03       Impact factor: 5.799

4.  Detection of hepatocellular carcinoma arising in cirrhotic livers: comparison of gadolinium- and ferumoxides-enhanced MR imaging.

Authors:  Y Tang; Y Yamashita; A Arakawa; T Namimoto; K Mitsuzaki; Y Abe; K Katahira; M Takahashi
Journal:  AJR Am J Roentgenol       Date:  1999-06       Impact factor: 3.959

5.  Three-dimensional dynamic liver MR imaging using sensitivity encoding for detection of hepatocellular carcinomas: comparison with superparamagnetic iron oxide-enhanced mr imaging.

Authors:  Young Kon Kim; Chong Soo Kim; Hyo Sung Kwak; Jeong Min Lee
Journal:  J Magn Reson Imaging       Date:  2004-11       Impact factor: 4.813

6.  Nontumorous hepatic arterial-portal venous shunts: MR imaging findings.

Authors:  J S Yu; K W Kim; M G Jeong; J T Lee; H S Yoo
Journal:  Radiology       Date:  2000-12       Impact factor: 11.105

7.  Detection of malignant hepatic tumors: comparison of gadolinium-and ferumoxide-enhanced MR imaging.

Authors:  M Matsuo; M Kanematsu; K Itoh; K Ito; Y Maetani; H Kondo; N Kako; N Matsunaga; H Hoshi; J Shiraishi
Journal:  AJR Am J Roentgenol       Date:  2001-09       Impact factor: 3.959

8.  Gd-EOB-DTPA enhanced MRI for hepatocellular carcinoma: quantitative evaluation of tumor enhancement in hepatobiliary phase.

Authors:  Kazuhiro Saito; Fumio Kotake; Naoki Ito; Taizo Ozuki; Ryuji Mikami; Kimihiko Abe; Yoko Shimazaki
Journal:  Magn Reson Med Sci       Date:  2005       Impact factor: 2.471

9.  Signal changes in liver and spleen after Endorem administration in patients with and without liver cirrhosis.

Authors:  W Hundt; R Petsch; T Helmberger; M Reiser
Journal:  Eur Radiol       Date:  2000       Impact factor: 5.315

10.  Differentiation of hypervascular hepatic pseudolesions from hepatocellular carcinoma: value of single-level dynamic CT during hepatic arteriography.

Authors:  K Ueda; O Matsui; Y Kawamori; M Kadoya; J Yoshikawa; T Gabata; A Nonomura; T Takashima
Journal:  J Comput Assist Tomogr       Date:  1998 Sep-Oct       Impact factor: 1.826

View more
  4 in total

1.  Small (≤ 2 cm) hepatocellular carcinoma in patients with chronic liver disease: comparison of gadoxetic acid-enhanced 3.0 T MRI and multiphasic 64-multirow detector CT.

Authors:  J Hwang; S H Kim; M W Lee; J Y Lee
Journal:  Br J Radiol       Date:  2011-12-13       Impact factor: 3.039

2.  Gadoxetic acid-enhanced MRI for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: can hypointensity on the late portal venous phase be used as an alternative to washout?

Authors:  Kyoung A Baek; Seung Soo Kim; Hyeong Cheol Shin; Jeong Ah Hwang; Seo-Youn Choi; Woong Hee Lee; Chan Ho Park; Hyoung Nam Lee; Nam Hun Heo
Journal:  Abdom Radiol (NY)       Date:  2020-09

3.  Validation of contrast-enhanced magnetic resonance imaging to monitor regenerative efficacy after cell therapy in a porcine model of convalescent myocardial infarction.

Authors:  Konstantinos Malliaras; Rachel R Smith; Hideaki Kanazawa; Kristine Yee; Jeffrey Seinfeld; Eleni Tseliou; James F Dawkins; Michelle Kreke; Ke Cheng; Daniel Luthringer; Chak-Sum Ho; Agnieszka Blusztajn; Ileana Valle; Supurna Chowdhury; Raj R Makkar; Rohan Dharmakumar; Debiao Li; Linda Marbán; Eduardo Marbán
Journal:  Circulation       Date:  2013-09-23       Impact factor: 29.690

4.  APASL and AASLD Consensus Guidelines on Imaging Diagnosis of Hepatocellular Carcinoma: A Review.

Authors:  Cher Heng Tan; Su-Chong Albert Low; Choon Hua Thng
Journal:  Int J Hepatol       Date:  2011-04-19
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.